During this hour-long panel discussion at Bio Integrates 2021, tranScrip's Managing Partner, Flic Gabbay, joined other health care professionals to discuss how to accelerate the development, assessment and approval of medicines outside of a pandemic.
- Ian Muir, Chief Executive Officer, Porton Biopharma
- Paul Stott, Chief Executive Office, Seda Pharmaceutical Development Services
- Jill Reckless, Chief Executive Officer, RxCelerate
- Flic Gabbay, Managing Partner, tranScrip
- Sandy Douglas, Research Group Leader, The University of Oxford
- Nick Smith, Associate Director of Operations, Cobra Biologics